17TH ST. GALLEN INTERNATIONAL BREAST CANCER CONFERENCE 2021

Primary Therapy of Early Breast Cancer
Evidence, Controversies, Consensus

17 – 21 March 2021,
online worldwide

www.sg-bcc.org
# TABLE OF CONTENT

- Important contacts ................................................................. 3
- Welcome .................................................................................. 4
- Committees ............................................................................... 5
- St.Gallen International Breast Cancer Award 2021 ...................... 7
- Eso Umberto Veronesi Memorial Award .................................... 9
- Scientific programme information .......................................... 10
- General conference information ................................................ 11
- Your virtual congress platform .................................................. 14
- Session types ........................................................................... 16
- On-demand sessions .................................................................. 17
- Live discussion sessions ............................................................ 23
- St.Gallen Consensus Panelists .................................................... 26
- Faculty members ...................................................................... 28
- Satellite Symposia ................................................................. 33
- Sponsors, exhibitors and partners ............................................. 48
IMPORTANT CONTACTS

SCIENTIFIC PROGRAMME, FACULTY

St.Gallen Oncology Conferences (SONK)
c/o Tumor and Breast Center ZeTuP
Rorschacherstrasse 150
9006 St.Gallen / Switzerland
+41 71 243 00 32
info@oncoconferences.ch
www.sg-bcc.org

INDUSTRIAL EXHIBITION,
SATELLITE SYMPOSIA, REGISTRATION,
ABSTRACT SUBMISSION

Mondial GmbH & Co. KG,
Mondial Congress & Events
Operngasse 20b, 1040 Vienna, Austria
bcc21@mondial-congress.com
www.mondial-congress.com

Email address during the conference:
bcc21-support@mondial-congress.com

www.sg-bcc.org
On behalf of the Conference Chairpersons, the International Scientific Programme Committee and the organisers, The Foundation St. Gallen Oncology Conferences (St. Gallen/Switzerland) welcomes you to the 17th edition of this important, biennial conference on “Primary Therapy of Early Breast Cancer”. As in the past, we expect delegates from many more than 100 countries worldwide to attend this unique teaching event, which will again highlight the “state of the art” of present optimal diagnostics and most efficient multi-modal primary treatment of women with breast cancer in its presently recognised forms of clinical, pathological and molecular-biologic presentations. This world-renowned conference, with its traditional, highly appreciated closing “St.Gallen International Breast Cancer Consensus Session” on the currently optimal treatment of early, localised breast cancer, again links scientists worldwide. However, due to the COVID-19 pandemic, this time we had to make challenging decisions: instead of travelling to and meeting in beautiful Vienna/Austria, we will meet fully virtual. We adapt to this new reality and look forward to meet online with professionals from even more countries and participants from all over the world. The successful scope and spirit, as well as the programme structure of the internationally well established St. Gallen International Breast Cancer Conference, basically remains unchanged with pre-recorded on-demand lectures and with the closing consensus session. In addition, special, time-sensitive live discussion sessions in the afternoon of the conference days will serve to debate issues arising from the pre-recorded on-demand sessions. A carefully selected international teaching faculty, and a highly competent consensus panel of around 60 top breast cancer experts from Europe, North America, Brazil, Asia and Australia, will lead the audience safely through the increasingly complex issues of optimally treating patients with the various new molecular entities of primary localised breast cancer, with the aim of increasing long-term cure rates, decreasing unpleasant treatment side-effects and long-term sequelae. Paying tribute to the developments and course of time, some changes have been introduced in the chairmanship of the conference and in the composition of the consensus panel. We appreciate your participation and look forward to another challenging conference of the highest scientific standards. We wish you a stimulating conference and sincerely hope that you will enjoy the virtual, scientific exchange with numerous colleagues from breast cancer centers and study groups from around the globe.

On behalf of the organising and scientific chairpersons:

— Professor Dr. med. Beat Thürlimann
Breast Center St. Gallen
Kantonsspital St. Gallen
Swiss Group for Clinical Cancer Research (SAKK)
St.Gallen / Switzerland

— Professor Michael Gnant, MD FACS
Professor of Surgery
Comprehensiv Cancer Center
Medical University
Vienna / Austria

— Professor Dr. Walter Weber
Chair of Breast Surgery
University Hospital
Basel / Switzerland

— Professor Dr. med. Hans-Jörg Senn
Conference Founder and Honorary Chair
Foundation St.Gallen Oncology Conferences (SONK)
c/o Tumor- and Breast Center ZeTuP
St. Gallen / Switzerland
COMMITTEES

PATRONAGE BY PROFESSIONAL SOCIETIES AND FOUNDATIONS

ABCSG
(Austrian Breast & Colorectal Cancer Study Group, www.abcsg.org), Austria

ASCO
(American Society of Clinical Oncology, www.asco.org), USA

BIG
(Breast International Group, www.bigagainstbreastcancer.org), Belgium

Chinese Breast Cancer Society

Foundation SONK
(St.Gallen Oncology Conferences, www.oncoconferences.ch), Switzerland

IBCSG
(International Breast Cancer Study Group, www.ibcsg.org), Italy/USA

SAKK
(Swiss Group for Clinical Cancer Research, www.sakk.ch), Switzerland
COMMITTEES

CONFERENCE CHAIRS

Conference founder and honorary chair
Hans-Joerg Senn, c/o Tumor and Breast Center ZeTuP
St.Gallen/Switzerland

Conference co-chairs
Michael Gnant, Medical University of Vienna/Austria
Beat Thürlimann, Breast Center St.Gallen, Kantonsspital St.Gallen/Switzerland

Scientific programme–chairpersons
Harold Burstein, Boston/MA, USA
Giuseppe Curigliano, Milano/Italy
Michael Gnant, Vienna/Austria
Meredith Regan, Boston/MA, USA
Hans-Jörg Senn, St.Gallen/Switzerland
Beat Thürlimann, St.Gallen/Switzerland
Walter Weber, Basel/Switzerland
Eric Winer, Boston/MA, USA

Extended international scientific committee, speakers and panelists

Aapro Matti (Switzerland)  Gamal Heba (Egypt)
Aebi Stefan (Switzerland)  Garber Judy (United States)
André Fabrice (France)  Giordano Sharon (United States)
Barrios Carlos (Brazil)  Gnant Michael (Austria)
Bergh Jonas (Sweden)  Gradishar William (United States)
Bonnefoi Herve (France)  Gulluoglu Bahadir (Turkey)
Bretel Morales Denisse (Peru)  Harbeck Nadia (Germany)
Brucker Sara (Germany)  Heil Jörg (Germany)
Burstein Harold (United States)  Huang Chiun-Sheng (Taiwan)
Cameron David (United Kingdom)  Huober Jens (Switzerland)
Cardoso Fatima (Portugal)  Ilbawi Andre (WHO Cancer Control Programme)
Carey Lisa (United States)  Jiang Zefei (China)
Cescon Dave (Canada)  Johnston Steven (United Kingdom)
Chua Boon (Australia)  King Tari (United States)
Ciruelos Eva (Spain)  Krop Ian (United States)
Coates Alan (Australia)  Lee Eun Sook (Korea)
Colleoni Marco (Italy)  Lin Nancy (United States)
Cortes Javier (Spain)  Loi Sherene (Australia)
Curigliano Giuseppe (Italy)  Loibl Sibylle (Germany)
Delaloge Suzette (France)  Morrow Monica (United States)
Denkert Carsten (Germany)  Pagani Olivia (Switzerland)
Dubsky Peter (Switzerland)  Partridge Ann (United States)
Ejlertsen Bent (Denmark)  Piccart Martine (Belgium)
Fitzal Florian (Austria)  Poormans Philip (Belgium)
Francis Prudence (Australia)  Prat Aleix (Spain)
Galimberti Viviana (Italy)  Pusic Andrea (United States)

Regan Meredith (United States)
Rubio Isabella (Spain)
Rugo Hope (United States)
Rutgers Emiel (Netherlands)
Sedlmayer Felix (Austria)
Semiglazov Vladimir (Russian Federation)
Shao Zhiming (China)
Spanic Tanja (Europa Donna)
Tesarova Petra (Czech Republic)
Thürlimann Beat (Switzerland)
Tjulandin Sergei (Russian Federation)
Toi Masakazu (Japan)
Trudeau Maureen (Canada)
Turner Nicholas (United Kingdom)
Tutt Andrew (United Kingdom)
Vaz Luis Ines (France)
Viale Giuseppe (Italy)
Watanabe Toru (Japan)
Weber Walter (Switzerland)
Winer Eric (United States)
Xu Binghe (China)
ST. GALLEN INTERNATIONAL BREAST CANCER AWARD 2021

The Foundation Council of “St.Gallen Oncology Conferences” (SONK) proudly announces the recipient of the “St.Gallen International Breast Cancer Award 2021”, which will be delivered during the 17th St.Gallen International Breast Cancer Conference, 17 – 21 March 2021 to:

Prof. Philip Poortmans
Iridium Netwerk & University of Antwerp
Antwerp, Belgium

Philip Poortmans MD PhD completed his medical studies at the University of Antwerp, Belgium and trained radiation oncology at the Middelheim and Vincentius Hospitals in Antwerp. After working 23 years as radiation oncologist in Tilburg, The Netherlands, he chaired the department of radiation oncology of the Radboud umc, Nijmegen. Via the same position at Institut Curie, Paris, France, he completed the circle by returning in 2020 to Antwerp. Since October 2020, he is associate professor at the University of Antwerp, Belgium.

Philip Poortmans is former president of the European Society for Radiotherapy and Oncology (ESTRO) and of the European Cancer Organisation and has been very active in the European Organisation for Research and Treatment of Cancer (EORTC). He is passionate about teaching, as evident from his role as course director and liaison person for different multidisciplinary courses of ESTRO and as faculty member for educational activities of the European Society for Medical Oncology (ESMO), European Society of Surgical Oncology (ESSO) and the European School of Oncology (ESO). Over the years, Philip Poortmans has contributed actively to the organisation of several scientific and educational events. He is member of the editorial committees of several guidelines for breast cancer (EUSOMA; ESTRO; ESMO; St Gallen) and for cancer and pregnancy (ESGO / INCIP; ESMO; AKZ (Adviesgroep Kanker en Zwangerschap); ABCIP). In addition, he co-chairs ECCO’s Quality Cancer Care Network with a coordinating role for the “Essential requirements for quality cancer care”.
Philip Poortmans is member of the editorial board of more than 10 journals, several concerning breast cancer such as “THE BREAST”, of which he is specialty editor for radiation oncology.

Philip Poortmans’ work focussed especially on breast cancer and since recently, what might become a great combination, in FLASH radiation therapy and IOeRT. For this, he is medical advisor for Sordina IORT Technologies, Aprilia, Italy. His PhD thesis was on quality assurance in clinical trials in breast cancer, successfully defended in 2005 at the University of Maastricht. He was an important contributor and PI of several clinical trials including the EORTC “Boost” trial, the EORTC “Internal Mammary Node” trial, the BOOG “Young Boost” trial, the partial breast “IRMA” trial and now the “EUROPA” trial. All those studies aim at precisely tailoring the extent of radiation therapy for breast cancer patients.

Philip Poortmans received honorary memberships of BVRO/ABRO (Belgium) in 2012, of ESSO in 2014, of SEOR (Spain) in 2015, of AROI (India) in 2016, of BIGOSA (South Africa) in 2016 and of JASTRO (Japan) in 2017. He was nominated as “Toparts” (Outstanding doctor) by the Dutch radiation oncologists in 2011 and 2012. In 2016, he gave the Cridlan lecture to the Association of Breast Surgery in Manchester, UK. Philip Poortmans received from ESTRO the Jens Overgaard Award in 2019 and the Klaas Breur Award in 2020. On the 150th birthdate of Marie Curie he was nominated Marie Curie Professor Paris Science & Lettres – Institut Curie. He (co-)authored more than 325 peer-reviewed publications (https://pubmed.ncbi.nlm.nih.gov/?term=Poortmans+P&sort=date) and several book chapters and co-edited 2 books.

St.Gallen Oncology Conferences (SONK) is privileged to count on Prof. Philip Poortmans as an active contributor and supporter of the St.Gallen International Breast Cancer Conference and Consensus. As a radiation oncologist, he added his scientific and professional perspective to provide truly interdisciplinary discussions for the benefit of the best treatment of women with early breast cancer. With the St.Gallen Breast Cancer Award 2021 the Foundation SONK wishes to honour Philip Poortmans for his extraordinary contributions. Thank you Philip!
ESO UMBERTO VERONESI MEMORIAL AWARD

The European School of Oncology (ESO) is proud to confer the Umberto Veronesi Memorial Award during the 17th St.Gallen International Breast Cancer Conference, 17 – 21 March 2021, to Fatima Cardoso for her outstanding contributions in the field.

Fatima Cardoso, MD  
Breast Unit, Champalimaud Clinical Center  
Lisbon, Portugal

Dr Cardoso is the Director of the Breast Unit of the Champalimaud Clinical Center (CCC) in Lisbon, Portugal. She is board certified in medical oncology and internal medicine.

Dr Cardoso earned her medical degree at the University of Porto in Portugal and completed fellowships in the Translational Research Unit of the Jules Bordet Institute (IJB) in Brussels, Belgium, and the Department of Molecular and Cellular Oncology at MD Anderson Cancer Center in Houston, Texas. She then worked for 10 years as Assistant Professor at the Medical Oncology Clinic of the IJB and served as the scientific director of the international research network TRANSBIG for 7 years (EU Framework VI). She returned to Portugal in October 2010 to create the Breast Unit of the CCC, leading it to become the 1st certified breast unit in Portugal.

Her research interests include biology of breast cancer, prognostic and predictive markers of response to systemic therapy, and new anticancer agents. She is actively involved in many phase I-IV breast cancer clinical trials.

Dr Cardoso is actively involved in numerous professional organizations such as ESO, ESMO, EORTC, ASCO, and AACR where she serves on several committees. She has been a member of several Board of Directors namely ESMO, ECCO and EORTC. Dr Cardoso founded and is founder and President of the Advanced Breast Cancer (ABC) Global Alliance and of the ABC International Consensus Guidelines Conference.

She is editor-in-chief of The Breast Journal, associate editor of the European Journal of Cancer, and an editorial board member of several other journals.

She has received several educational and research grants from the Breast Cancer Research Foundation, the European Society of Medical Oncology, the European Cancer Organization, the Portuguese Science and Technology Foundation, the Portuguese League Against Cancer, the Susan G. Komen Foundation, and the European Union.

She was awarded the prestigious Order of Santiago da Espada for Scientific Merit, from the President of Portugal, on June 10th 2015. She has also received the Flims Alumni Club (FAC) Lifetime Achievement Award 2011; the Prix Nice – St Paul 2017, for the work developed for Advanced Breast Cancer Patients; the Reach to Recovery International Health Professional Award 2019, for exceptional contributions by a health professional in the field of breast cancer support; and the ABC Award 2019, in recognition of her foresight in understanding the importance of advanced breast cancer and for launching a Global Alliance against it.

Dr Cardoso has authored about 300 publications and has presented her work nationally and internationally.
Participants can obtain a certificate of attendance after the conference upon completing a short questionnaire. The questionnaire will be sent via email on Tuesday, 23 March 2021.

The conference programme is accredited with 10 European CME credits by the European Union of Medical Specialists (EACCME). This Accreditation is recognised by the AMA (American Medical Association) and the Physicians Recognition Award (PRA) in the United States as well as by respective accreditations in PR China and Japan.

We appreciate the high amount of profound and interesting contributions, submitted as abstracts for the 17th St.Gallen International Breast Cancer Conference 2021 on the following topics:

- Adjuvant systemic therapy
- Biology/Pathology/Basic Research
- Epidemiology/Prevention/Diagnosis
- Locally advanced disease
- Radiotherapy/IORT
- Neoadjuvant (pre-operative) therapy
- Health politics/Guidelines
- Predictive and prognostic factors
- Surgery/Sentinels/DCIS
- Survivorship issues
- Other

Within the virtual conference, all accepted submissions will be displayed in an ePoster gallery, which will be accessible from Wednesday, 10 March 2021. You will be able to contact abstract presenters via the meeting hub, which is the networking area within the conference platform.

All abstracts will be published in an electronic supplement issue to the journal “THE BREAST” by Elsevier Publishers. The respective link can be found on the conference website from Wednesday, 17 March 2021 onwards.

The scientific committee honours the three best poster abstracts with the St.Gallen Oncology Conferences Best Poster Award 2021. All three awards are endowed with a prize money of EUR 500.00. The awardees will be presented in a virtual poster ceremony on Friday 19 March 2021, 12.00-12.30 (CET). The St.Gallen Oncology Conferences Best Poster Awards are sponsored by the Foundation St.Gallen Oncology Conferences.

The proceedings of the conference (only invited presentations) will also be published as a supplement to the journal “THE BREAST” by Elsevier. The proceedings are sponsored by the Foundation St.Gallen Oncology Conferences and by Elsevier.

The consensus recommendations will be published some months after the conference in the Journal ‘Annals of Oncology’ by Elsevier.
GENERAL CONFERENCE INFORMATION

REGISTRATION FEES

<table>
<thead>
<tr>
<th></th>
<th>Regular fee from 1 February 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular participants</td>
<td>EUR 395.00</td>
</tr>
<tr>
<td>Students/residents in training*</td>
<td>EUR 125.00</td>
</tr>
<tr>
<td>Nurses*</td>
<td>EUR 125.00</td>
</tr>
<tr>
<td>Emerging economies**</td>
<td>EUR 125.00</td>
</tr>
</tbody>
</table>

In order to be eligible for the respective reduced fee, please provide:
*A letter from the Head of the Department
**Emerging economies: Applies to individuals from low and lower-middle-income economies according to the World Bank listing

THE REGISTRATION FEE INCLUDES

- online access to the virtual conference
- private login code for one device
- possibility to interact with speakers (Q&A), attendees (networking area) and industry representatives (virtual exhibition)
- exclusive access to SG-BCC webcasts
- admission to the virtual industrial exhibition
- admission to the virtual poster exhibition
- certificate of attendance upon submission of an online feedback questionnaire after the conference

Registration will remain open until the last day of the conference!
GENERAL CONFERENCE INFORMATION

BOOKING & CANCELLATION CONDITIONS

Access to the virtual conference platform will only be provided if the full pre-payment of the applicable registration fee is received by Mondial Congress & Events.

The registration is personalized and cannot be transferred. Only registered delegates will receive access to the virtual conference platform. It is not permitted to share any access information.

Mondial Congress & Events reserves the right to change or cancel your bookings, in case you fail to make payment in due time, or do not qualify for and/or provide proof for the selected registration fee.

All handling/modification fees stated (for early cancellations and name changes) are net, before any VAT.

For all prices stated: In the event that new, higher legal charges are introduced, these will be added to the contract price. Any refunds will be made after the conference.

REGISTRATION

Registration fees for the congress are stated in Euro and include 20% VAT.

Please note, that the day of payment receipt is decisive for the registration fee.

(Early Fee - payment by Sunday, 31 January 2021; Regular Fee - payment from Monday, 1 February 2021)

Cancellations must be made in writing to the conference secretariat, Mondial Congress & Events. If received before Sunday, 31 January 2021, all fees, except for a cancellation handling fee of EUR 40.00 net will be refunded. No refunds will be made after this date.

For name changes a modification fee of EUR 10.00 net will be charged.

VIRTUAL INDUSTRIAL EXHIBITION

The virtual exhibition will be open from 1 hour before the first session to 20 minutes after the last session.

Wednesday, 17 March 2021 09:30 – 18:35
Thursday, 18 March 2021 11:00 – 19:50
Friday, 19 March 2021 11:45 – 18:35

Access to the industry exhibition: You can access the industrial exhibition directly from the timeline. The virtual exhibition features an overview of all exhibitors, by clicking ‘View/Visit’ on the respective booths you can find further information about the company. During the opening times of the exhibition you will also be able to have a video call or a chat with the exhibitor to find out more about their products and company developments.

In case an exhibitor is currently not available or you visit the exhibition outside of the exhibition opening times, you may also send a contact request to specific employees in order to connect with them at a later point. Please note that by sending a connection request you also agree to share your personal data with the respective staff member in order for them to follow up with you.
GENERAL CONFERENCE INFORMATION

LANGUAGE

The official conference language is English. Simultaneous translations will not be provided.

NETWORKING OPPORTUNITIES – MEETING HUB

You have the option to connect with other delegates in the ‘meeting hub’ and stay in touch throughout the conference. Once you are connected with another delegate, you can start private live chats or video calls at any point during the conference and also schedule meetings for a later time. The meeting hub is a great way to connect with other delegates during the conference and share your thoughts and impression of the sessions.

LEAD RETRIEVAL FOR INDUSTRY SYMPOSIA

When accessing company sponsored symposia, a pop-up window will notify participants that their personal data collected by Mondial Congress & Events upon registration (name, organisation/institute, address and contact details), will be passed on to the respective company which may contact them later on for their own purposes.

This declaration of consent can be retracted at any time by sending a written message to Mondial Congress & Events, Operngasse 20B, 1040 Vienna or to dataprotection@mondial-congress.com.

There is no lead retrieval in the virtual exhibition but you may share your personal data with a company by sending or accepting a connection request via the meeting hub.
DETAILS

1. Timeline
The timeline is the navigation page of the virtual congress platform – aside of viewing the daily programme, you will be able to access all other congress areas from here.
All pre-recorded lectures will be available on-demand starting 10 March, 09:00 CET. When accessing the congress platform the on-demand lectures can be found on the current day between 10 – 16 March.

2. Scientific Sessions
You can join a session by clicking on it on the timeline – while viewing the sessions you can also interact with the speakers and other delegates via the Q&A tool.

3. Meeting hub
You have the option to connect with other delegates in the ‘meeting hub’ and stay in touch throughout the congress. Once you are connected with another delegate, you can start private live and video chats at any point during the conference and also schedule meetings for a later time.

4. Virtual Poster exhibition
You can have a look at the ePosters of the submitted abstracts in the virtual poster exhibition.

5. Virtual Industrial exhibition
Visit the industrial exhibition to meet our industry partners. You will be able to find interesting product information and videos from all sponsors. Furthermore, you can have a live chat or request a meeting to find out more about the products they offer.

6. SG-BCC 2021 Engage & Connect
Complete the SG-BCC 2021 treasure hunt, collect points and win one of our attractive prizes!

Participate in our treasure hunt by taking advantage of the interactive features in the different conference areas! You can collect points for your contribution to the conference by interacting with other delegates during presentations, by visiting the poster and industrial exhibition and by finding the answers to the questions of the day.

The top 3 contestants will receive the following prizes:

1. Prize: A free registration including a ticket for the congress evening at the 18th St.Gallen International Breast Cancer Conference 2023 in Vienna
2. Prize: A free registration for SG-BCC 2023 in Vienna
3. Prize: A free ticket to the congress evening at SG-BCC 2023 in Vienna

The virtual conference platform will remain open until Friday, 26 March 2021. All on-demand scientific lectures will be accessible starting Friday, 10 March 2021 until then.
SESSION TYPES

ON-DEMAND SESSIONS
All pre-recorded lectures will be available on-demand starting Wednesday, 10 March, 09:00 CET. When accessing the congress platform the on-demand lectures can be found on the current day between 10-16 March. Thereafter, the on-demand lectures can be found on the timeline on 16 March for the remainder of the congress. You may watch the on-demand lectures anytime you like and we greatly encourage audience members to ask their questions already while watching the videos prior to the start of the live programme. All questions posted in the Q&A section during the on-demand sessions will be collected and selected by the chairs and the most interesting questions will be addressed in the respective live discussion sessions. All discussion sessions will also become available on-demand the day after their live slot.

LIVE DISCUSSION SESSIONS
During the live discussion sessions taking place from Wednesday, 17 March to Friday, 19 March 2021, all speakers from the respective on-demand session will be present live to further discuss their lectures. Discussions will be facilitated by distinguished chairs and co-chairs. Questions and discussion points can be submitted by registered participants either already while watching the on-demand lectures (strongly preferred!), but also during the live discussion sessions. Join our live discussion sessions to be part of the scientific dialogue!

ST.GALLEN INTERNATIONAL BREAST CANCER CONSENSUS SESSIONS
The St.Gallen International Breast Cancer Conference 2021 will close as usual with an update of the widely acknowledged St.Gallen International Breast Cancer Consensus on the optimal treatment of early breast cancer. Once again, a carefully selected international teaching faculty, and a highly competent consensus panel of some 60 top breast cancer experts from Europe, North America, South America, Australia and Asia, will lead the audience safely through the increasingly complex issues of optimally treating patients with the various new molecular entities of primary localised breast cancer, with the aim of increasing long-term cure rates, decreasing treatment side-effects and long-term sequelae. In order to allow even more room for discussions on early breast cancer care, the 2021 Consensus will be split out over the weekend, taking place on Saturday afternoon, 20 March, and Sunday afternoon, 21 March 2021, 14.00-17.00 (CET), for the first time. The consensus session will not be recorded but only available live.

INDUSTRY SPONSORED SATELLITE SYMPOSIAS
Industry-sponsored satellite symposia will take place live between Wednesday, 17 March and Friday, 19 March 2021 with some companies offering their lectures to be available on demand starting 10 March also. This year, the companies offer a large variety of formats, ranging from classic lectures to discussion-sessions with Q&A, panel discussions and much more.

WEBCASTS
The webcasts of the pre-recorded on-demand sessions and the live discussion sessions from 17 to 19 March 2021 will be available to all delegates on the website www.sg-bcc.org starting from Monday, 22 March 2021. The webcasts are exclusively supported by Veracyte.
# ON-DEMAND SESSIONS

Accelerating access to innovation in early breast cancer

## Session 1: News in breast cancer care since St. Gallen 2019: Challenges and Opportunities

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unmet challenges in systemic therapy</td>
<td>Harold Burstein, USA</td>
</tr>
<tr>
<td>Breast surgery – where do we go?</td>
<td>Michael Gnant, Austria</td>
</tr>
<tr>
<td>What patients want: Tradeoffs, preferences and thresholds</td>
<td>Tanja Spanic, Europa Donna</td>
</tr>
<tr>
<td>Accelerating progress to innovation for patients: Trial design and risk stratification</td>
<td>Meredith Regan, USA</td>
</tr>
<tr>
<td>Global challenges in breast cancer detection and treatment</td>
<td>Carlos Barrios, Brazil</td>
</tr>
</tbody>
</table>

## Session 2: Care for patients with HER2-positive breast cancer

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neoadjuvant and adjuvant treatment</td>
<td>Nadia Harbeck, Germany</td>
</tr>
<tr>
<td>HER2 heterogeneity</td>
<td>Aleix Prat, Spain</td>
</tr>
<tr>
<td>Can we prevent brain metastases?</td>
<td>Nancy Lin, USA</td>
</tr>
<tr>
<td>Accelerating progress from advanced to early breast cancer</td>
<td>Hope Rugo, USA</td>
</tr>
</tbody>
</table>

## Session 3: Care for patients with ER+ breast cancer

<table>
<thead>
<tr>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjuvant endocrine therapy (pre- and postmenopausal)</td>
<td>Eric Winer, USA</td>
</tr>
<tr>
<td>Neoadjuvant endocrine therapy</td>
<td>Steven Johnston, UK</td>
</tr>
<tr>
<td>Why does endocrine therapy work and why does it stop working</td>
<td>Fabrice André, France</td>
</tr>
<tr>
<td>Accelerating progress from advanced to early breast cancer</td>
<td>Dave Cescon, Canada</td>
</tr>
</tbody>
</table>

15 min. per lecture
## ON-DEMAND SESSIONS

### Session 4: Predictive and prognostic biomarkers in patients with breast cancer

- **Tumor infiltrating lymphocytes** *(Carsten Denkert, Germany)*
- **Genomic changes with therapy and detection of molecular recurrence** *(Nicholas Turner, UK)*
- **Is lobular breast cancer different and should it be treated differently?** *(William Gradishar, USA)*
- **Genomic tests for selecting therapy in adjuvant treatment of ER+ breast cancer** *(Martine Piccart, Belgium)*
- **Genetic testing in patients with triple negative or hereditary breast cancer** *(Judy Garber, USA)*

### Special lecture I

**Integrating CDK 4-6 in the treatment of patients with early breast cancer** *(Sibylle Loibl, Germany)*

### Session 5: Optimal locoregional therapy: treating the axilla in women with breast cancer

- **Axillary surgery in node-positive breast cancer** *(Walter Weber, Switzerland)*
- **Omitting surgical staging of the axilla** *(Tari King, USA)*
- **Risk adapted regional node irradiation** *(Philip Poortmans, France)*
- **Adjuvant decision making in the era of limited nodal information** *(Sharon Giordano, USA)*

### Session 6: Local treatment of patients with breast cancer

- **Standards in breast conservation and oncoplastic surgery** *(Florian Fitzal, Austria)*
- **Breast surgery after neoadjuvant treatment** *(Jörg Heil, Germany)*
- **Type/timing of reconstruction when post-mastectomy radiotherapy is planned** *(Andrea Pusic, USA)*
- **State of the art in DCIS: who needs surgery, radiotherapy, endocrine therapy** *(Boon Chua, Australia)*
ON-DEMAND SESSIONS

Session 7: Optimal care for women with triple negative breast cancer

- Neoadjuvant and adjuvant treatment (Lisa Carey, USA)
- Immuno-oncology treatment in early stage TNBC (Sherene Loi, Australia)
- Accelerating progress from advanced to early breast cancer for TNBC (Giuseppe Curigliano, Italy)
- Surgery and prophylactic surgery in hereditary breast cancer (Monica Morrow, USA)
- PARP inhibitors in treatment of early stage breast cancer (Andrew Tutt, UK)

Session 8: Caring for breast cancer survivors

- Lifestyle and sexual health (Inez Vaz Luis, France)
- Late toxicity of treatment (including bone health) (Bent Ejlertsen, Denmark)
- Fertility preservation (Olivia Pagani, Switzerland)
- Surveillance and follow-up (Ann Partridge, USA)

Session 9: Neoadjuvant approach in patients with early breast cancer

- Evaluation of the breast cancer patient (patient assessment, staging, planning) (Isabella Rubio, Spain)
- Pathology after neoadjuvant treatment – how to assess residual disease (Giuseppe Viale, Italy)
- The meaning of residual disease (Ian Krop, USA)
- How to work together – the coordination of the multidisciplinary breast team (Emiel Rutgers, The Netherlands)
ON-DEMAND SESSIONS

Session 10: Special treatment challenges in patients with early breast cancer

- Management of breast cancer in elderly patients (Matti Aapro, Switzerland)
- Management of breast cancer in men (Fatima Cardoso, Portugal)
- Locally advanced breast cancer (Stephan Aebi, Switzerland)
- Oligometastatic disease – optimal treatment for long-term survival (Javier Cortes, Spain)
- Optimizing care in cultures with limited resources: choices and priorities (Andre Ilbawi, WHO Cancer Control Programme)
## LIVE DISCUSSION SESSIONS

Accelerating access to innovation in early breast cancer

<table>
<thead>
<tr>
<th>Time</th>
<th>Wednesday, 17 March 2021</th>
<th>Thursday, 18 March 2021</th>
<th>Friday, 19 March 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30-12.00 (CET)</td>
<td>Industry Sponsored Satellite Symposium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00-12.30 (CET)</td>
<td></td>
<td>ESO Umberto Veronesi Memorial Award PRE-RECORDED</td>
<td>St.Gallen Oncology Conferences Best Poster Award 2021 PRE-RECORDED</td>
</tr>
<tr>
<td>14.00-14.40 (CET)</td>
<td>Session 2: Care for patients with HER2-positive breast cancer</td>
<td>Session 5: Optimal locoregional therapy: treating the axilla in women with breast cancer</td>
<td>Session 7: Optimal care for women with triple negative breast cancer</td>
</tr>
<tr>
<td>14.55-15.35 (CET)</td>
<td>Session 3: Care for patients with ER+ breast cancer</td>
<td>Session 6: Local treatment of patients with breast cancer</td>
<td>Session 8: Caring for breast cancer survivors</td>
</tr>
<tr>
<td>18.30-19.30 (CET)</td>
<td>Industry Sponsored Satellite Symposium</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## LIVE DISCUSSION SESSIONS

<table>
<thead>
<tr>
<th>Time</th>
<th>Saturday, 20 March 2021</th>
<th>Sunday, 21 March 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30-12.00 (CET)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.00-12.30 (CET)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.30-13.00 (CET)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00-13.30 (CET)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30-14.00 (CET)</td>
<td>Aron Goldhirsch Memorial Lecture (PRE-RECORDED)</td>
<td>2021 St.Gallen International Breast Cancer Award (PRE-RECORDED)</td>
</tr>
<tr>
<td>14.00-17.00 (CET)</td>
<td>St. Gallen International consensus session on the optimal primary treatment of women with breast cancer 2021 Part I (DON'T MISS IT)</td>
<td>St. Gallen International consensus session on the optimal primary treatment of women with breast cancer 2021 Part II (DON'T MISS IT)</td>
</tr>
<tr>
<td>16.45-18.15 (CET)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.30-19.30 (CET)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
LIVE DISCUSSION SESSIONS

Accelerating access to innovation in early breast cancer

During the live discussion sessions, all speakers from the respective on-demand session will be present live to further discuss their lectures. Discussions will be facilitated by distinguished moderators and chairs. Questions and discussion points can be submitted by registered participants either already while watching the on-demand lectures (strongly preferred!), but also during the live discussion sessions. Please note that Session 1 “News in breast cancer care since St.Gallen 2019: Challenges and Opportunities” will not be discussed live.

WEDNESDAY, 17 MARCH 2021

14.00-14.40 (CET)  Session 2: Care for patients with HER2-positive breast cancer  
Chair: Harold Burstein (USA)  
Co-Chairs: Sibylle Loibl (Germany), Carlos Barrios (Brazil)

14.55-15.35 (CET)  Session 3: Care for patients with ER+ breast cancer  
Chair: Michael Gnant (Austria)  
Co-Chairs: Philip Poortmans (Belgium), Masakazu Toi (Japan)

15.50-16.30 (CET)  Session 4: Predictive and prognostic biomarkers in patients with breast cancer  
Chair: Beat Thürlimann (Switzerland)  
Co-Chairs: Giuseppe Viale (Italy), Aleix Prat (Spain)
LIVE DISCUSSION SESSIONS

THURSDAY, 18 MARCH 2021

12.00-12.30 (CET)  ESO Umberto Veronesi Memorial Award Lecture
De-escalation of early breast cancer therapy: Umberto Veronesi’s legacy.
Fatima Cardoso (Portugal)
Introduction by Franco Cavalli (Switzerland)

14.00-14.40 (CET)  Session 5: Optimal locoregional therapy: treating the axilla in women with breast cancer
Chair: Walter Weber (Switzerland)
Co-Chairs: Michael Gnant (Austria), Meredith Regan (USA)

14.55-15.35 (CET)  Session 6: Local treatment of patients with breast cancer
Chair: Monica Morrow (USA)
Co-Chairs: Sherene Loi (Australia), Zhiming Shao (China)

15.50-16.30 (CET)  Session 9: Neoadjuvant approach in patients with early breast cancer
Chair: Sibylle Loibl (Germany)
Co-Chairs: Giuseppe Curigliano (Italy), Nadia Harbeck (Germany)

FRIDAY, 19 MARCH 2021

12.00-12.30 (CET)  St.Gallen Oncology Conferences Best Poster Award 2021
Introduction by Walter Weber (Switzerland)

14.00-14.40 (CET)  Session 7: Optimal care for women with triple negative breast cancer
Chair: Giuseppe Curigliano (Italy)
Co-Chairs: David Cameron (United Kingdom), Carlos Barrios (Brazil)

14.55-15.35 (CET)  Session 8: Caring for breast cancer survivors
Chair: Meredith Regan
Co-Chairs: Ann Partridge (USA), Eun Sook Lee (Korea)

15.50-16.30 (CET)  Session 10: Special treatment challenges in patients with early breast cancer
Chair: Fatima Cardoso (Portugal)
Co-Chairs: Beat Thürlimann (Switzerland), Carlos Barrios (Brazil)
SATURDAY, 20 MARCH 2021 –
ST.GALLEN INTERNATIONAL BREAST CANCER CONSENSUS SESSION – PART I

Aron Goldhirsch Lecture – This is a new lecture, devoted to one of the first and prominent chairing team members and supporter of the St.Gallen International Breast Cancer Conference.

13.30-14.00 (CET)  
Aron Goldhirsch Memorial Lecture  
Evolution of adjuvant therapies across the time and the future of cooperative academic clinical research groups, David Cameron (United Kingdom)  
Introduction by Alan Coates (Australia)  
Co-Chair: Michael Gnant (Austria)

14.00-17.00 (CET)  
St.Gallen International consensus session on the optimal primary treatment of women with breast cancer 2021 – 2023 – Part I  
Chair: Eric Winer (USA)  
Co-Chairs: Harold Burstein (USA), Giuseppe Curigliano (Italy), Michael Gnant (Austria), Meredith Regan (USA), Beat Thürlimann (Switzerland), Walter Weber (Switzerland)

SUNDAY, 21 MARCH 2021 –
ST.GALLEN INTERNATIONAL BREAST CANCER CONSENSUS SESSION – PART II

13.30-14.00 (CET)  
2021 St.Gallen International Breast Cancer Award Lecture  
The contribution of radiotherapy to personalised care of patients with early breast cancer, Philip Poortmans (Belgium)  
Introduction by Beat Thürlimann (Switzerland)  
Co-Chair: Giuseppe Curigliano (Italy)

14.00-17.00 (CET)  
St.Gallen International consensus session on the optimal primary treatment of women with breast cancer 2021 – 2023 – Part II  
Chair: Eric Winer (USA)  
Co-Chairs: Harold Burstein (USA), Giuseppe Curigliano (Italy), Michael Gnant (Austria), Meredith Regan (USA), Beat Thürlimann (Switzerland), Walter Weber (Switzerland)
ST. GALLEN CONSENSUS PANELISTS

Jens Huober (Germany)
Martine Piccart (Belgium)
Emiel Rutgers (The Netherlands)
Beat Thürlimann (Switzerland)
Giuseppe Viale (Italy)

Andre Ilbawi (WHO Cancer Control Programme)
Philip Poortmans (Belgium)
Vladimir Semiglazov (Russia)
Sergei Tjulandin (Russia)
Toru Watanabe (Japan)

Steven Johnston (UK)
Aleix Prat (Spain)
Zhiming Shao (PR China)
Masakazu Toi (Japan)
Walter Weber (Switzerland)

Sibylle Loibl (Germany)
Meredith Regan (USA)
Felix Sedlmayer (Austria)
Maureen Trudeau (Canada)
Eric P. Winer (USA)

Monica Morrow (USA)
Isabella Rubio (Spain)
Tanja Spanic (Europa Donna)
Nicholas Turner (UK)
Binghe Xu (PR China)

Ann Partridge (USA)
Hope Rugo (USA)
Petra Tesarova (Czech Republic)
Inez Vaz Luis (France)
Jiang Zefei (PR China)
FACULTY MEMBERS

Aapro Matti, Genolier Cancer Centre, Genolier, Switzerland

Aebi Stefan, Tumorzentrum LUKS, Luzerner Kantonsspital, Lucerne, Switzerland

André Fabrice, Institut de Cancérologie Gustave Roussy, Villejuif, France

Barrios Carlos, Centro de Pesquisa em Oncologia, Hospital São Lucas, PUCRS, Porto Alegre, Brazil

Bergh Jonas, Karolinska Institutet and University Hospital, Stockholm, Sweden

Bonnefoi Herve, University of Bordeaux 2, Bordeaux, France

Bretel Morales Denisse, Oncosalud, Lima, Peru

Brucker Sara, Universitäts-Frauenklinik Tübingen, Tübingen, Germany

Burstein Harold, Dana-Farber Cancer Institute, Boston, United States

Cameron David, The University of Edinburgh, Edinburgh, United Kingdom

Cardoso Fatima, Champalimaud Cancer Center, Lisbon, Portugal

Carey Lisa, UNC - Lineberger Comprehensive Cancer Center, Chapel Hill, United States

Cescon Dave, Princess Margaret Hospital, Toronto, Canada

Chua Boon, Prince of Wales Hospital, Randwick, Australia

Ciruelos Eva, University Hospital 12 de Octubre, Madrid, Spain

Coates Alan, University of Sydney, Australia

Colleoni Marco, European Institute of Oncology, Milano, Italy

Cortes Javier, International Breast Cancer Center, Barcelona, Spain

Curigliano Giuseppe, European Institute of Oncology, Milano, Italy

Delaloge Suzette, Institut de Cancérologie Gustave Roussy, Villejuif, France

Denkert Carsten, Institut für Pathologie, Charité - Universitätsmedizin Berlin, Berlin, Germany

Dubsky Peter, Brustzentrum Hirslanden Klinik St. Anna, Lucerne, Switzerland

Ejlertsen Bent, DBCG Secretariat and Dept. of Oncology, Rigshospitalet, Copenhagen, Denmark

Fitzal Florian, Medical University Vienna, Vienna, Austria

Francis Prudence, Peter McCallum Cancer Centre, Melbourne, Australia

Galimberti Viviana, European Institute of Oncology, Milano, Italy

Gamal Heba, National Cancer Institute, Cairo, Egypt

Garber Judy, Dana-Farber Cancer Institute, Boston, United States
## FACULTY MEMBERS

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Giordano Sharon</td>
<td>The University of Texas MD Anderson Cancer Center, Houston, United States</td>
</tr>
<tr>
<td>Gnant Michael</td>
<td>Medical University Vienna, Vienna, Austria</td>
</tr>
<tr>
<td>Gradishar William</td>
<td>Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine,</td>
</tr>
<tr>
<td></td>
<td>Northwestern University, Chicago, United States</td>
</tr>
<tr>
<td>Gulluoglu Bahadir</td>
<td>Marmara University School Of Medicine, Istanbul, Turkey</td>
</tr>
<tr>
<td>Harbeck Nadia</td>
<td>Frauenkliniken Maistrasse-Innenstadt und Großhadern, Munich, Germany</td>
</tr>
<tr>
<td>Heil Jörg</td>
<td>Heidelberg University, Heidelberg, Germany</td>
</tr>
<tr>
<td>Huang Chiun-Sheng</td>
<td>National Taiwan University Hospital, Taipei, Taiwan</td>
</tr>
<tr>
<td>Huober Jens</td>
<td>Kantonsspital St.Gallen, St.Gallen, Switzerland</td>
</tr>
<tr>
<td>Ilbawi Andre</td>
<td>WHO Cancer Control Program, Switzerland</td>
</tr>
<tr>
<td>Jiang Zefei</td>
<td>307 Hospital No.8, Beijing, China</td>
</tr>
<tr>
<td>Johnston Steven</td>
<td>Royal Marsden Hospital, London, United Kingdom</td>
</tr>
<tr>
<td>King Tari</td>
<td>Dana-Farber Cancer Institute, Boston, United States</td>
</tr>
<tr>
<td>Krop Ian</td>
<td>Dana-Farber Cancer Institute, Boston, United States</td>
</tr>
<tr>
<td>Lee Eun Sook</td>
<td>National Cancer Center, Goyang-si, Korea</td>
</tr>
<tr>
<td>Lin Nancy</td>
<td>Dana-Farber Cancer Institute, Boston, United States</td>
</tr>
<tr>
<td>Loi Sherene</td>
<td>Peter McCallum Cancer Centre, Melbourne, Australia</td>
</tr>
<tr>
<td>Loibl Sibylle</td>
<td>GBG Forschungs GmbH, Neu-Isenburg, Germany</td>
</tr>
<tr>
<td>Morrow Monica</td>
<td>Memorial Sloan-Kettering Cancer Center, New York, United States</td>
</tr>
<tr>
<td>Pagani Olivia</td>
<td>Institute of Oncology Southern Switzerland, Bellinzona, Switzerland</td>
</tr>
<tr>
<td>Partridge Ann</td>
<td>Dana-Farber Cancer Institute, Boston, United States</td>
</tr>
<tr>
<td>Piccart Martine</td>
<td>Institut Jules Bordet, Brussels, Belgium</td>
</tr>
<tr>
<td>Poortmans Philip</td>
<td>Iridium Kankernetwerk &amp; University of Antwerp, Antwerp, Belgium</td>
</tr>
<tr>
<td>Prat Aleix</td>
<td>Hospital Clinic of Barcelona, Barcelona, Spain</td>
</tr>
<tr>
<td>Pusic Andrea</td>
<td>Brigham and Women’s Hospital, Boston, United States</td>
</tr>
<tr>
<td>Regan Meredith</td>
<td>Dana-Farber Cancer Institute, Boston, United States</td>
</tr>
<tr>
<td>Rubio Isabella</td>
<td>Clinica Universidad de Navarra, Madrid, Spain</td>
</tr>
<tr>
<td>Rugo Hope</td>
<td>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States</td>
</tr>
<tr>
<td>Rutgers Emiel</td>
<td>Netherlands Cancer Institute, Amsterdam, Netherlands</td>
</tr>
</tbody>
</table>
FACULTY MEMBERS

Sedlmayer Felix, Paracelsus Medical University, Salzburg, Austria

Semiglazov Vladimir, N.N.Petrov Research Institute of Oncology, St. Petersburg, Russian Federation

Shao Zhiming, Fudan University Cancer Hospital, Shanghai, China

Spanic Tanja, Europa Donna, Ljubljana, Slovenia

Tesarova Petra, Charles University Hospital and 1st medical faculty, Prague, Czech Republic

Thürlimann Beat, Kantonsspital St.Gallen, St.Gallen, Switzerland

Tjulandin Sergei, N.N. Blokhin Cancer Research Center, Moscow, Russian Federation

Toi Masakazu, Graduate School of Medicine Kyoto University, Kyoto City, Japan

Trudeau Maureen, University of Toronto, Toronto, Canada

Turner Nicholas, The Royal Marsden Hospital, London, United Kingdom

Tutt Andrew, Breast Cancer Now Research Centre, London, United Kingdom

Vaz Luis Ines, Institut de Cancérologie Gustave Roussy, Villejuif, France

Viale Giuseppe, Istituto Europeo di Oncologia, Milano, Italy

Watanabe Toru, Hamamatsu Oncology Center, Hamamatsu, Japan

Weber Walter, Klinik für Allgemeinchirurgie, Universitätsspital Basel, Basel, Switzerland

Winer Eric P., Dana-Farber Cancer Institute, Boston, United States

Xu Binghe, National Cancer Center, Beijing, China
18th St. Gallen International Breast Cancer Conference 2023

Primary Therapy of Early Breast Cancer
Evidence, Controversies, Consensus

15 – 18 March 2023, Vienna/Austria

St. Gallen Oncology Conferences (SONK)
c/o Tumor and Breast Center ZeTuP
Rorschacherstrasse 150, 9006 St. Gallen / Switzerland
sg-bcc@oncoconferences.ch, www.sg-bcc.org
When Recurrence Is in the Cards: Recognizing and Addressing Risk in Patients With HR-Positive, HER2-Negative Early Breast Cancer

Presented by leading experts in the field
Dr. William J. Gradishar, MD, FASCO, FACP, and Prof. Nadia Harbeck, MD

**Activity Objective**
After this activity, learners will be able to identify women with HR-positive, HER2-negative early breast cancer who are at high risk of disease recurrence, and propose current and emerging therapeutic strategies that may improve patient outcomes.

**Virtual Satellite Symposium**
10:30 – 12:00 CET

- Welcome and Introduction (10 min)
- Identifying Which Way the Deck Is Stacked for Patients With Early Breast Cancer (10 min)
- Showing Your Cards When it Comes to Risk Assessment for Early Breast Cancer (10 min)
- Addressing the Cards Dealt With Evolving Treatment for Early Breast Cancer (10 min)
- Using the Cards Up Your Sleeve to Optimize Treatment for Early Breast Cancer (10 min)
- Questions and Take Home Learnings

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

This symposium is neither sponsored nor endorsed by St. Gallen International Breast Cancer Conference.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and Answers in CME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.

This CME activity is jointly provided by Oakstone Publishing and Answers in CME.
WHEN RECURRENCE IS IN THE CARDS: RECOGNIZING AND ADDRESSING RISK IN PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER

Faculty: William J. Gradishar, USA
        Nadia Harbeck, Germany

Welcome and Introductions

Identifying Which Way the Deck is Stacked for Patients with Early Breast Cancer

Showing Your Cards When it Comes to Risk Assessment for Early Breast Cancer

Addressing the Cards Dealt with Evolving Treatment for Early Breast Cancer

Using the Cards Up Your Sleeve to Optimize Treatment for Early Breast Cancer

Questions and Take Home Learnings

Engage in Discussion with the Experts

Please join us as we hear from two leading oncologists as they discuss how to identify women with HR-positive, HER2-negative early breast cancer who are at high risk of disease recurrence, and propose current and emerging adjuvant treatment strategies that may lead to improved patient outcomes. Watch as Professor Nadia Harbeck and Dr. William Gradishar bring Answer in CME’s unique virtual live experience to life using flashcards along with engaging discussion so that after viewing you’ll be better able to:

- Recognize prognostic factors associated with a higher risk of recurrence in patients with HR-positive, HER2-negative, early-stage breast cancer
- Apply clinical approaches to optimize the identification of patients with high-risk features associated with disease recurrence
- Illustrate the use of individualized, evidence-based treatment strategies to optimize outcomes of patients with high-risk HR-positive, HER2-negative early-stage breast cancer
### St. Gallen 2021 Satellite Symposium

**Advancing care for patients with early breast cancer**

**Watch on demand from:**

**Wednesday, 10th March 2021**

**or during the congress on:**

**Wednesday, 17th March 2021, 12:15-13:40**

**Online Worldwide**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15–12:20</td>
<td><strong>Welcome and introduction</strong></td>
<td>Dr Giampaolo Bianchini (Italy)</td>
</tr>
<tr>
<td>12:20–12:40</td>
<td><strong>Making optimal treatment decisions for patients with HER2-positive eBC</strong></td>
<td>Dr Giampaolo Bianchini</td>
</tr>
<tr>
<td>12:40–12:50</td>
<td><strong>Improving treatment beyond efficacy for patients with HER2-positive eBC</strong></td>
<td>Prof. Christian Jackisch (Germany)</td>
</tr>
<tr>
<td>12:50–13:10</td>
<td><strong>The role of cancer immunotherapy in the treatment of patients with early triple negative breast cancer</strong></td>
<td>Prof. Peter Schmid (UK)</td>
</tr>
<tr>
<td>13:10–13:20</td>
<td><strong>Beyond efficacy: Patient-reported outcomes from cancer immunotherapy trials in early triple negative breast cancer</strong></td>
<td>Dr Elizabeth Mittendorf (USA)</td>
</tr>
<tr>
<td>13:20–13:35</td>
<td><strong>Panel discussion</strong></td>
<td></td>
</tr>
<tr>
<td>13:35–13:40</td>
<td><strong>Meeting close</strong></td>
<td>Dr Giampaolo Bianchini</td>
</tr>
</tbody>
</table>
ADVANCING CARE FOR PATIENTS WITH EARLY BREAST CANCER

Welcome and introduction
Dr Giampaolo Bianchini, Italy

Making optimal treatment decisions for patients with HER2-positive eBC
Dr Giampaolo Bianchini, Italy

Improving treatment beyond efficacy for patients with HER2-positive eBC
Prof. Christian Jackisch, Germany

The role of cancer immunotherapy in the treatment of patients with early triple negative breast cancer
Prof. Peter Schmid, UK

Beyond efficacy: Patient-reported outcomes from cancer immunotherapy trials in early triple negative breast cancer
Dr Elizabeth Mittendorf, USA

Panel discussion
Moderated by Dr Giampaolo Bianchini, Italy

Meeting close
Dr Giampaolo Bianchini, Italy

Although impressive advances have been made in treating early breast cancer, we are still all striving to cure more patients. We look forward to seeing you online for a discussion on the latest data in HER2-positive and triple negative early breast cancer and how these recent developments could be integrated into the wider early breast cancer treatment landscape.

Wednesday 17 March | 16:45–18:15 CET

The value of experience:
Improving patient outcomes in a new era of clinical evidence

Prof Giuseppe Curigliano
European Institute of Oncology, Milan, Italy

Dr Paul Cottu
Institut Curie, Paris, France

Prof Winson Cheung
The University of Calgary, Calgary, Canada

This meeting is organised and funded by Pfizer
© 2021 Pfizer Pharma GmbH. All rights reserved
January 2021. PP-IBR-GLB-0500

Insert: FP_ad_Pfizer
In this exciting symposium, Professor Giuseppe Curigliano (Milan, Italy) will be joined by an expert faculty and, together with Dr Paul Cottu (Paris, France) and Professor Winson Cheung (Calgary, Canada), will discuss the growing evidence base for use of CDK4/6 inhibitors as standard of care in HR-positive, HER2-negative metastatic breast cancer as well as the latest evidence for CDK4/6 inhibitors in the adjuvant setting.

Following this, Dr Paul Cottu (Paris, France) will review how recent advancements in our understanding of specific mutations have resulted in promising new treatment strategies, particularly regarding the use of PARP inhibitors in patients with germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer.

In addition, Dr Paul Cottu, together with Professor Winson Cheung, will discuss the emerging role of real-world evidence in increasing our understanding of clinical trial data and their applicability to the broader populations of patients treated in our practices.

Finally, we will look to the future to consider how emerging treatment strategies for HR-positive, HER2-negative metastatic breast cancer can further improve patient outcomes.

Thank you and we look forward to working together to improve outcomes for our patients.
Experts exploring HER2CLIMB

Live session: 18 March 2021
12:45–13:45 CET
Available on demand from: 10 March 2021

Chair Speaker: Dr Stephanie Sutherland
Speakers: Prof. Sibylle Loibl and Dr Mafalda Oliveira

Join us as, through dynamic interviews, our experts discuss their opinions and share their insights into the HER2CLIMB study of tucatinib in patients with HER2+ MBC.

- Introduction and Understanding the HER2CLIMB study design
- Exploring the data: HER2CLIMB efficacy and safety
- Diving deeper: HER2CLIMB subgroups
- Live Q&A and short closing statement
Join us as we explore the HER2CLIMB trial in patients with HER2+ metastatic breast cancer. Our esteemed Chair, Dr Stephanie Sutherland leads our panel of experts through a series of dynamic interviews answering key questions on the study, in this important patient population. Using an innovative format, tucatinib clinical trial data will be presented through narrated animations with the panel of experts providing clinical context throughout.

Through this session you will be able to submit your questions to the faculty. After the interviews have concluded, the panel will answer your queries during a live Q&A session.
**16:45–16:50**  
**Opening remarks**  
Prof. Jean-Yves Pierga (Co-Chair)  
Institut Curie, Paris, France

**16:50–17:00**  
**The innovative mode of action of next-generation antibody–drug conjugates (ADCs)**  
Prof. Matthias Peipp  
Christian-Albrechts-University, Kiel, Germany

**17:00–17:15**  
**Next-generation ADCs in the treatment of advanced breast cancer**  
Prof. Rupert Bartsch  
Medical University of Vienna, Vienna, Austria

**17:15–17:30**  
**New hope for HER2: Early intervention in HER2-positive breast cancer**  
Prof. Sibylle Loibl  
German Breast Group, Neu Isenburg, Germany

**17:30–17:45**  
**New recommendations for HER2: Guideline update**  
Prof. Fatima Cardoso  
Breast Unit, Champalimaud Clinical Centre, Lisbon, Portugal

**17:45–18:10**  
**New paradigm for HER2: Place of the next-generation ADCs in the treatment landscape**  
Panel discussion and Q&A, all speakers

**18:10–18:15**  
**Closing remarks**  
Prof. Nadia Harbeck (Co-Chair)  
Breast Center, University of Munich (LMU), Germany
NEXT-GENERATION ANTIBODY-DRUG CONJUGATES: NEW HOPE FOR HER2

Opening remarks
Jean-Yves Pierga, France (Co-Chair)

The innovative mode of action of next-generation antibody-drug conjugates (ADCs)
Matthias Peipp, Germany

Next-generation ADCs in the treatment of advanced breast cancer (ABC)
Rupert Bartsch, Austria

New hope for HER2: Early intervention in HER2-positive breast cancer
Sibylle Loibl, Germany

New recommendations for HER2: Guideline update
Fatima Cardoso, Portugal

New paradigm for HER2: Place of the next-generation ADCs in the treatment landscape
All speakers
Panel Discussion and Q&A

Closing remarks
Nadia Harbeck, Germany (Co-Chair)

Despite the availability of a number of HER2-targeted therapies, patients with advanced/metastatic HER2-positive breast cancer continue facing the challenges of disease progression, treatment resistance and brain metastases. Response rate and overall life expectancy decrease with each additional line of therapy, and tumour heterogeneity remains an issue. Next-generation HER2-targeted antibody–drug conjugates (ADCs) have shown promising results in preclinical and clinical studies and are undergoing further clinical testing.

We will discuss the medical needs of patients with metastatic HER2+ breast cancer and how ADC development can be tailored to meet these needs. We will cover the mechanism of action of the next-generation ADCs, summarise the clinical efficacy and safety results of HER2-targeted ADCs in metastatic breast cancer and discuss the studies of ADCs in high-risk early disease. We invite you to join what promises to be a lively and interactive discussion of the most recent developments in the field.
Unprecedented survival in HR+/HER2- aBC.

MORE LIFE*

No asterisk needed. The longest overall survival reported for any CDK4/6 inhibitor—KISQALI.

Nearly 5 years median OS in premenopausal women¹

Results from an ad hoc exploratory analysis of the MONALEESA-7 trial (median follow-up of 54 months): 58.7 months with KISQALI + AI vs 47.7 months with placebo + AI; HR=0.798 (95% CI: 0.615-1.035). OS improvement previously demonstrated in the ITT population (median follow-up of 35 months): KISQALI + AI/tamoxifen vs placebo arm (HR=0.71; 95% CI: 0.54-0.95; \(P=0.00973\)).¹²

Learn more at KISQALI.com

KISQALI is not indicated for concomitant use with tamoxifen.³

Indications

- KISQALI is indicated for the treatment of women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy
- In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist

Please see full Summary of Product Characteristics.


aBC, advanced breast cancer; AI, aromatase inhibitor; CDK, cyclin-dependent kinase; HR, hazard ratio; ITT, intent to treat; OS, overall survival.

This is a global campaign driving to a global website and is not country specific.
SATELLITE SYMPOSIA

THURSDAY, 18 MARCH
18:30-19:30 CET

REIMAGINING TREATMENT OF HR+, HER2– EBC

Speakers: Aleix Prat, Spain
           Giuseppe Curigliano, Italy

Opening remarks

Recurrence Risk: A Clinical or Genomic Assessment?

Who May Benefit from CDK4/6i in the EBC Setting?

What Might the Future Look Like in EBC?

Live Q&A session

Closing remarks

CDK4/6 inhibitors (CDK4/6is) are the standard of care for HR+, HER2– advanced breast cancer. Although clinicians are enthusiastic about CDK4/6is as an emerging option in early breast cancer (EBC), many unanswered questions remain. Join us for a lively and interactive discussion on this highly anticipated new therapeutic option.
Prediction of chemotherapy benefit was established for N0 patients based on NSABP B-20 study, and for N1 post-menopausal patients based on SWOG-8814 study. TAILORx and RxPONDER refined the chemotherapy benefit estimates for patients with Recurrence Score results 11–25 and Recurrence Score results 0–25 respectively.

References:

HR+=hormone receptor positive; HER2–=human epidermal growth factor receptor 2 negative; N0/nodes-negative; N1/nodes-positive (up to 3 positive nodes); TAILORx= Trial Assigning Individualized Options for Treatment; RxPONDER= a clinical trial Rx for POsitive NoDe, Endocrine Responsive breast cancer.

It’s never been as clear

Predicting chemotherapy benefit

TAILORx and RxPONDER establish the Oncotype DX® test as standard of care

HR+=hormone receptor positive; HER2–=human epidermal growth factor receptor 2 negative; N0/nodes-negative; N1/nodes-positive (up to 3 positive nodes); TAILORx= Trial Assigning Individualized Options for Treatment; RxPONDER= a clinical trial Rx for POsitive NoDe, Endocrine Responsive breast cancer.

Oncotype DX Breast Recurrence Score and Oncotype DX are registered trademarks of Genomic Health, Inc. Exact Sciences is a registered trademark of Exact Sciences Corporation. © 2021 Genomic Health, Inc. All rights reserved. EXS12587_I220_EN_INT
CONFIDENCE IN TREATMENT DECISIONS FOR HR+, HER2- EARLY BREAST CANCER PATIENTS

Chair: Mark Harries, UK

Recent landmark RxPONDER results: impact on treatment decisions for node-positive patients
Suzette Delaloge, France

An integrated view of the latest clinical evidence
Giuseppe Curigliano, Italy

What will we do on Monday morning?
Patient cases and discussion
Moderated by Mark Harries with the entire panel

The RxPONDER (Kalinsky et al., 2020) trial successfully defined the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Oncotype DX Breast Recurrence Score® results of 0-25.1 First results from the study, led by the independent SWOG Cancer Research Network and sponsored by the National Cancer Institute (NCI), identified a majority of postmenopausal women with 1-3 positive nodes who received no benefit from chemotherapy.

RxPONDER showed a different effect of chemotherapy based on Recurrence Score® results for postmenopausal and premenopausal women. Postmenopausal women with Recurrence Score results 0-25 were not observed to show benefit from chemotherapy and may avoid the side effects of the treatment. Importantly, no chemotherapy benefit was observed, regardless of the number of affected nodes, tumour grade, or size. Two-thirds of the women in the trial were postmenopausal.

The first results also demonstrated, after a median of five years of follow-up, that premenopausal women with Recurrence Score results 0-25 were observed to have a statistically significant chemotherapy benefit, with an average improvement in distant recurrence rates at 5 years of 3%.

Listen in to hear top experts, including an investigator of the RxPONDER trial, discuss how these results could impact clinical practice.

EXTEND HER PROTECTION AGAINST BREAST CANCER RECURRENCES

Patient cases in HER2+ early breast cancer
EXTEND HER PROTECTION AGAINST BREAST CANCER RECURRENCES
PATIENT CASES IN HER2+ EARLY BREAST CANCER

Welcome and introduction
Prof. S. Loibl (Chair), Germany

Practice update | Evolving concepts in HER2+/HR+ early breast cancer
Prof. S. Loibl

Managing risk | A patient with node-positive HER2+/HR+ breast cancer after adjuvant treatment
Prof. R. Bartsch, Austria

Check the narrative | Preventing recurrence in a patient after neoadjuvant therapy
Dr. J. O’Shaughnessy, USA
Panel questions (All)

HER experience | Understanding the patient’s perspective
Panel discussion
All faculty joined by Ms Laure Guérout-Accolas, Patients en réseau

Live Q&A and close
Prof. S. Loibl

This year’s Pierre Fabre Satellite Symposium EXTEND HER PROTECTION AGAINST BREAST CANCER RECURRENCES - Patient cases in HER2+ early breast cancer explores the role of extended adjuvant therapy within recommended practice for HER2+/HR+ early breast cancer.

Our esteemed faculty will give a practice update on the role of extended adjuvant therapy within recommended practice and highlight the current challenges and unmet need regarding disease recurrence for patients with HER2+ early breast cancer after neoadjuvant and/or adjuvant therapies.

The presentations will cover current treatment pathways and guidelines in early breast cancer, introduce the concept of extended adjuvant anti-HER2 therapy and, using patient case-based discussions, explore the treatment options currently approved in this setting.

During the panel discussion, our faculty will be joined by a patient representative to discuss the patient’s perspective and reinforce the importance of joint decision-making. The panel discussion will focus on how to optimally communicate about risk of recurrence with patients and how to improve patient understanding and involvement in treatment decisions in order to increase treatment adherence.

A live Q&A session will follow directly after the panel discussion, where you will have an opportunity to have your questions answered by our expert panel.
SPONSORS, EXHIBITORS AND PARTNERS OF THE SG-BCC 2021

We would like to express our pleasure and gratitude of the support and commitment from the following organisations and companies

SPONSORS

Agendia www.agendia.com
Hologic https://hologicbreastcancer.com/eur/
Natera https://www.natera.com/oncology/signatera-advanced-cancer-detection/
Paxman https://paxmanscalpcooling.com/
SPONSORS, EXHIBITORS AND PARTNERS

CO-OPERATING PARTNERS

Chinese Breast Cancer Society

International Breast Cancer Study Group

SAKK

SONK

PROMOTIONAL PARTNERS

Endorsed by ESTRO

European School of Oncology

GBG

GBCC10

Healing through innovation, competence and partnership

Oncoplastic Breast Consortium

Universimed

www.sg-bcc.org
European School of Oncology

Oncology e-learning
Your free education just one click away!

Keep up-to-date via #e_ESO
www.e-eso.net

e-Learn
with our experts, discussants and materials

Access
any materials available on the site at any time

Connect LIVE
on Thursday at 18:15 CET

Interact
by asking questions to our experts BEFORE, DURING and AFTER the live sessions

Get
CME credits

Create
your own e-ESO agenda

- Grandrond Sessions - sessions on hot-topics
- Highlights Sessions - key takeaways from major international events
- From ESO Events - speeches given during selected ESO conferences
- Debate Sessions - discussions about differing opinions
- Oncoreview Sessions - balanced and comprehensive overview of a specific topic
- Clinical Case Sessions - discussions of clinical cases
- Oncology Basics - sessions on the basics of oncology
- Social Media Sessions

- Recorded sessions - live sessions that have been recorded and remain available online
- Future live sessions - scheduled sessions that are presented live online and offer interaction between speaker, discussant and participants
- Downloadable PDF presentations from past ESO events

Selected e-ESO educational materials have been organised into PATHWAYS: a series of sessions on a specific topic that provide a general overview. After completing a pathway, the attendee will be able to download a certificate of attendance.
Advanced Breast Cancer

ABC6
Sixth Advanced Breast Cancer International Consensus Conference

4-6 November 2021
Lisbon, Portugal

Chair:
F. Cardoso, PT
Honorary Chairs:
Co-Chair:
R. Haidinger, DE
Scientific Committee Members:
N. S. El Saghir, LB - A. Eniu, CH
S. Paluch-Shimon, IL - F. Penault-Llorca, FR
H.S. Rugo, US - T. Wiseman, UK

The ABC6 guidelines will be developed by

The ABC6 guidelines are enforced by

The ABC6 conference is held with support from under the auspices of and is endorsed by

ABC6 will be followed by the meeting of the on 6-7 November 2021

ABC6 is being organised as an in person meeting, should this not be possible because of the pandemic, more information will follow.

RECEIVE UPDATES AT: www.abc-lisbon.org • #ABClisbon